

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 4	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 5	AUG 02	CAPLUS and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 6	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 7	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 8	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS 9	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS 10	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS 11	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 12	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS 13	SEP 27	STANDARDS will no longer be available on STN
NEWS 14	SEP 27	SWETSCAN will no longer be available on STN
NEWS 15	SEP 30	STN downtime scheduled October 2-3, 2004
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:25:26 ON 01 OCT 2004

=> file caplus uspatful japio europatful medline biosis embase scisearch		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 17:26:05 ON 01 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:26:05 ON 01 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 17:26:05 ON 01 OCT 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 17:26:05 ON 01 OCT 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 17:26:05 ON 01 OCT 2004

FILE 'BIOSIS' ENTERED AT 17:26:05 ON 01 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 17:26:05 ON 01 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:26:05 ON 01 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

=> s (accomodative amplitude) or presbyopia
L1 3182 (ACCOMODATIVE AMPLITUDE) OR PRESBYOPIA

=> s l1 and (break? or disrupt?) and (bonds or (disulfide bonds))
L2 30 L1 AND (BREAK? OR DISRUPT?) AND (BONDS OR (DISULFIDE BONDS))

=> s l2 and glutathione
L3 7 L2 AND GLUTATHIONE

=> s l3 and (energy or electromagnetic or sonic or particle or heat)
L4 6 L3 AND (ENERGY OR ELECTROMAGNETIC OR SONIC OR PARTICLE OR HEAT)

=> d l4 1-6 ibib abs

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:616201 CAPLUS
DOCUMENT NUMBER: 137:174935
TITLE: **Presbyopia** treatment by lens alteration
INVENTOR(S): Till, Jonathan S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002110549	A1	20020815	US 2002-50879	20020118
WO 2002056804	A2	20020725	WO 2002-US1404	20020118
WO 2002056804	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1370237 A2 20031217 EP 2002-709084 20020118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-262423P P 20010119
WO 2002-US1404 W 20020118

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying **energy** to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of **presbyopia** as well as treats it. By **breaking** and/or preventing the formation of **bonds** that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule. Biol. acceptable compds. comprise **glutathione** or thiols and enzymes such as **glutathione S-transferase** or thiol reductase can **break disulfide bonds**.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:142552 CAPLUS

DOCUMENT NUMBER: 136:178019

TITLE: **Presbyopia** treatment by lens alteration with reducing agents

INVENTOR(S): Till, Jonathan S.

PATENT ASSIGNEE(S): Refocus, LLC, USA

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013863	A2	20020221	WO 2001-US25576	20010816
WO 2002013863	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001083386 A5 20020225 AU 2001-83386 20010816

US 2002025311 A1 20020228 US 2001-930287 20010816

PRIORITY APPLN. INFO.: US 2000-225659P P 20000816
WO 2001-US25576 W 20010816

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying external **energy** to affect a change in the accommodative abilities of the human lens. By **breaking bonds** that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

L4 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2004:41451 USPATFULL
 TITLE: Keratinocyte growth factor-2
 INVENTOR(S): Ruben, Steven M., Brookeville, MD, United States
 Jimenez, Pablo, Chatham, NJ, United States
 Duan, D. Roxanne, Gaithersburg, MD, United States
 Rampy, Mark A., Montgomery Village, MD, United States
 Mendrick, Donna, Mount Airy, MD, United States
 Zhang, Jun, San Diego, CA, United States
 NI, Jian, Germantown, MD, United States
 Moore, Paul A., North Bethesda, MD, United States
 Coleman, Timothy A., Gaithersburg, MD, United States
 Gruber, Joachim R., Dallas, TX, United States
 Dillon, Patrick J., Carlsbad, CA, United States
 Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693077	B1	20040217
APPLICATION INFO.:	US 2000-610651		20000630 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-345373, filed on 1 Jul 1999 Continuation of Ser. No. US 1998-23082, filed on 13 Feb 1998, now patented, Pat. No. US 6077692 Continuation-in-part of Ser. No. US 1997-910875, filed on 13 Aug 1997 Continuation-in-part of Ser. No. US 1997-862432, filed on 23 May 1997 Division of Ser. No. US 1995-461195, filed on 5 Jun 1995 Continuation-in-part of Ser. No. WO 1995-US1790, filed on 14 Feb 1995 Continuation-in-part of Ser. No. US 610651 Continuation-in-part of Ser. No. US 1996-696135, filed on 13 Aug 1996 Continuation-in-part of Ser. No. US 1995-461195, filed on 5 Jun 1995 Continuation-in-part of Ser. No. WO 1995-US1790, filed on 14 Feb 1995		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205417P	20000519 (60)
	US 2000-198322P	20000419 (60)
	US 1999-171677P	19991222 (60)
	US 1999-163375P	19991103 (60)
	US 1999-149935P	19990819 (60)
	US 1999-148628P	19990812 (60)
	US 1999-144024P	19990715 (60)
	US 1999-143648P	19990714 (60)
	US 1999-142343P	19990702 (60)
	US 1997-39045P	19970228 (60)
	US 1997-55561P	19970813 (60)
	US 1996-23852P	19960813 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Saoud, Christine J.
 LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.
 NUMBER OF CLAIMS: 48
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 80 Drawing Figure(s); 64 Drawing Page(s)
 LINE COUNT: 16222

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter

referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:265887 USPATFULL
TITLE: Keratinocyte growth factor-2
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Jimenez, Pablo, Chatham, NJ, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Rampy, Mark A., Montgomery Village, MD, UNITED STATES
Mendrick, Donna, Mount Airy, MD, UNITED STATES
Zhang, Jun, Bethesda, MD, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
Gruber, Joachim R., Elizabethtown, KY, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186904	A1	20031002
APPLICATION INFO.:	US 2002-35212	A1	20020104 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-259853P	20010108 (60)
	US 2001-286368P	20010426 (60)
	US 2001-331168P	20011109 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 64 Drawing Page(s)
LINE COUNT: 17177
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:205862 USPATFULL
TITLE: Presbyopia treatment by lens alteration
INVENTOR(S): Till, Jonathan S., Salem, VA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002110549 A1 20020815
APPLICATION INFO.: US 2002-50879 A1 20020118 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-262423P 20010119 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON, 1500 K STREET, N.W., SUITE 700,
WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying **energy** to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of **presbyopia** as well as treats it. By **breaking** and/or preventing the formation of **bonds** that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:42947 USPATFULL
TITLE: **Presbyopia** treatment by lens alteration
INVENTOR(S): Till, Jonathan S., Salem, VA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002025311 A1 20020228
APPLICATION INFO.: US 2001-930287 A1 20010816 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-225659P 20000816 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON, 1500 K STREET, N.W., SUITE 700,
WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 472

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying external **energy** to affect a change in the accommodative abilities of the human lens. By **breaking bonds** that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.